Development and evaluation of 18F-labeled novel radiopharmaceuticals for PET imaging of fibroblast activation protein expressing tumors
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Qingyu Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 2…. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Fluorine Radioisotopes, Gelatinases, Positron-Emission Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Shanghai Key Laboratory of Molecular Imaging, School of Medicine, Shanghai Jiao Tong University, National Key Research and Development Program of China.
Abstract (Originalsprache)
This study aimed to develop and evaluate two novel 18F-labeled radiopharmaceuticals, [18F]AlF-NOTA-De-FAPI and [18F]AlF-NOTA-Glu-FAPI, for Positron Emission Tomography (PET) imaging of tumors expressing fibroblast activation protein. Molecular docking simulations predicted the binding affinities of NOTA-De-FAPI and NOTA-Glu-FAPI with FAP. The radiotracers were synthesized and evaluated for radiochemical yield, purity, and molar activity. Surface plasmon resonance analysis measured binding kinetics. In vitro and in vivo stability and distribution coefficients were assessed. PET/CT imaging and ex vivo biodistribution studies were conducted in U87MG tumor-bearing mice. A pilot clinical study compared [18F]AlF-NOTA-De-FAPI with [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG in a liver cancer patient. Molecular docking simulations showed that NOTA-De-FAPI had a slightly higher binding affinity for FAP. The radiotracers were synthesized with high purity and molar activity. SPR analysis confirmed higher binding affinity of NOTA-De-FAPI (KD = 86.35 pM) compared to NOTA-Glu-FAPI (KD = 187 pM). In PET/CT imaging, [18F]AlF-NOTA-De-FAPI demonstrated higher tumor uptake in U87MG tumor-bearing mice, with a peak SUVmax of 2.71 ± 0.39 at 1 h post-injection. Ex vivo biodistribution studies showed that [18F]AlF-NOTA-De-FAPI had a tumor uptake of 9.16 ± 0.49 %ID/g at 1 h post-injection, significantly higher than [18F]AlF-NOTA-Glu-FAPI (6.60 ± 0.82 %ID/g). In the clinical study, [18F]AlF-NOTA-De-FAPI showed strong uptake in the primary tumor but exhibited higher physiological uptake in salivary glands, thyroid, and pancreas compared to [68Ga]Ga-DOTA-FAPI-04. [18F]AlF-NOTA-De-FAPI demonstrated potential as a FAP-targeting tracer with high specific uptake and favorable tumor-to-normal tissue ratios in preclinical models. However, clinical evaluation revealed limitations, such as high physiological uptake in certain glands and lower tumor uptake compared to [68Ga]Ga-DOTA-FAPI-04. Further optimization and clinical validation are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China; MOE Key Lab of Resource Chemistry, Joint International R…
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China.
- MOE Key Lab of Resource Chemistry, Joint International Research Laboratory of Resource Chemistry of Ministry of Education, Shanghai Key Laboratory of Rare Earth Functional Materials, and Shanghai Frontiers Science Centr…
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China. Electronic address: nuclearj@163.com.
- Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 210000, China. Electronic address: wangch628@163.com.
Förderung
- Shanghai Key Laboratory of Molecular Imaging
- School of Medicine, Shanghai Jiao Tong University
- National Key Research and Development Program of China
- Shanghai Jiao Tong University
Zitieren
APA
Zhang, Q., Hu, Z., Zhao, H., Du, F., Lv, C., Peng, T., Zhang, Y., Zhang, B., Liu, J., & Wang, C. (2025). Development and evaluation of 18F-labeled novel radiopharmaceuticals for PET imaging of fibroblast activation protein expressing tumors. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108445
Vancouver
Zhang Q, Hu Z, Zhao H, Du F, Lv C, Peng T, et al. Development and evaluation of 18F-labeled novel radiopharmaceuticals for PET imaging of fibroblast activation protein expressing tumors. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108445
BibTeX
@article{Zhang2025,
author = {Zhang, Qingyu and Hu, Zhoumi and Zhao, Haitao and Du, Fuqiang and Lv, Chun and Peng, Tukang and Zhang, Yukai and Zhang, Bowu and Liu, Jianjun and Wang, Cheng},
title = {Development and evaluation of 18F-labeled novel radiopharmaceuticals for PET imaging of fibroblast activation protein expressing tumors},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108445}
}
EUVIMED